Background
Daniëla Katinka van Santen earned her bachelor’s degree in Nursing and soon after completed the pre-master Health Sciences at the VU University of Amsterdam. In 2012 she completed her master’s internship at the Public Health Service of Amsterdam (GGD Amsterdam) and the Royal Tropical Institute (KIT). In 2012 she obtained a cum laude master’s degree in Health Sciences, specialising in infectious diseases.
In May 2018, Daniëla completed her PhD training at the department of Infectious Disease Research and Prevention at the Public Health Service of Amsterdam under the supervision of Prof. Maria Prins, Dr. Ronald Geskus and Dr. Jannie van der Helm. Her PhD thesis is titled “Epidemiological studies on viral infections and co-infections: human immunodeficiency virus, hepatitis C virus and human papillomavirus”.
In 2016 she worked at the same institution as a researcher in the department of Epidemiology, Health Promotion and Care Innovation on the Amsterdam Health Monitoring study. Currently, Daniëla is working as a post-doctoral fellow at the Public Health Service of Amsterdam and the Burnet Institute.
Key interests: viral infections and co-infections (i.e. HIV and hepatitis C co-infection) affecting key populations such as gay and bisexual men and people who inject drugs. As well as public health and complex epidemiological and statistical methods to analyse longitudinal data.
Key projects:
- International Collaboration on Hepatitis C Elimination in HIV –Coinfection (InCHEHC) – including 11 HIV cohorts from 7 countries.
- HIV and HCV co-infection elimination among gay and bisexual men in Australia.
- Harm reduction revisited: assessing the causal effect of harm reductions programs on - - HIV and HCV acquisition among people who inject drugs. This is also a collaborative project, which will include data from the Amsterdam Cohort Studies (Public Health Service of Amsterdam, Amsterdam) the SuperMix cohort (Burnet Institute, Melbourne) and ALIVE cohort (Johns Hopkins University, Baltimore).
Positions
- 2017 – ongoing: Postdoctoral fellow at the Public Health Service of Amsterdam, the Netherlands
- 2018 – ongoing: Postdoctoral fellow at Burnet Institute, Melbourne, Australia
Qualifications
2018: PhD, University of Amsterdam, the Netherlands
2012: MSc, VU university, Amsterdam, the Netherlands
2010: BSc, Utrecht University of applied sciences, Utrecht, the Netherlands
Awards
- 2017: Spinoza travel award (Amsterdams Universiteit fonds) to attend the 6th International Symposium on Hepatitis Care in Substance Users (INHSU) – New York, USA
- 2017: Amsterdam Infection and Immunity travel grant – to attend the 20th International Workshop on HIV and Hepatitis Observational Databases (IWHOD) – Lisbon, Portugal
- 2017: Young investigator registration bursary – European Association for the Study of the Liver (EASL) – Amsterdam, the Netherlands
- 2016: Full scholarship award – 5th International Symposium on Hepatitis Care in Substance Users (INHSU) – Oslo, Norway
- 2016: Young investigator scholarship award – 21st AIDS conference – Durban, South Africa
- 2015: Best poster presentation – 15th European AIDS Conference (EACS), – Barcelona, Spain
- 2015: AMC young talent fund Louise Gunning Public Health Study Fund, specific Public Health course at Johns Hopkins University – Baltimore, USA
- 2015: Full scholarship award – 4th International Symposium on Hepatitis Care in Substance Users (INHSU) – Sydney, Australia
- 2014: Young investigator scholarship award – 21st Conference on Retroviruses and Opportunistic Infections (CROI) – Boston, USA
Projects (2)
Current (2)
Publications (27)
2023 (2)
- Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019.
van Santen DK, Sacks-Davis R, Stewart A, Boyd A, Young J, van der Valk M, Smit C, Rauch A, Braun DL, Jarrin I, Berenguer J, Lazarus JV, Lacombe K, Requena MB, Wittkop L, Leleux O, Salmon D, Bonnet F, Matthews G, Doyle JS, Spelman T, Klein MB, Prins M, Asselin J, Stoové MA, Hellard M; InCHEHC study group.
EClinicalMedicine. 2023 Feb; 56:101810
- Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: a pooled analysis of emulated trials.
van Santen DK, Lodi S, Dietze P, van den Boom W, Hayashi K, Dong H, Cui Z, Maher L, Hickman M, Boyd A, Prins M
Addiction. 2023 Jan; Epub ahead of print
2022 (2)
- Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs.
Traeger MW, van Santen DK, Sacks-Davis R, Asselin J, Carter A, Doyle JS, Pedrana A, Wilkinson AL, Howell J, Thatcher R, Didlick J, Donovan B, Guy R, Hellard ME, Stoové MA; Australia Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood Borne Viruses (ACCESS).
J Viral Hepat. 2022 Jun; 29(10):908-918
- The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009-2019.
Harney BL, Sacks-Davis R, van Santen DK, Traeger M, Wilkinson AL, Asselin J, El-Hayek C, Fairley CK, Roth N, Bloch M, Matthews G, Donovan B, Guy R, Stoové M, Hellard ME, Doyle JS; Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood-borne Viruses (ACCESS).
Clin Infect Dis. 2022 Jan; 74(10):1804-1811
2021 (5)
- A Feasibility Study to Increase Chronic Hepatitis C Virus RNA Testing and Linkage to Care among Clients Attending Homeless Services in Amsterdam, The Netherlands.
Generaal E, Logtenberg van der Grient H, Schatz E, Santen DKV, Boyd A, Woods SK, Baak BLC, Prins M
Diagnostics. 2021 Jun; 11(7):1197
- The effect of needle and syringe program and opioid agonist therapy on the risk of HIV, hepatitis B and C virus infection for people who inject drugs in Amsterdam, the Netherlands: findings from an emulated target trial.
van Santen DK, Anders B, Matser A, Maher L, Hickman M, Lodi S, Prins M
Addiction. 2021 Mar; 116(11):3115-3126
- Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.
Arum C, Fraser H, Artenie AA, Bivegete S, Trickey A, Alary M, Astemborski J, Iversen J, Lim AG, MacGregor L, Morris M, Ong JJ, Platt L, Sack-Davis R, van Santen DK, Solomon SS, Sypsa V, Valencia J, Van Den Boom W, Walker JG, Ward Z, Stone J, Vickerman P; Homelessness, HIV, and HCV Review Collaborative Group.
Lancet Public Health. 2021 Mar; 6(5):E309-E323
- Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective.
van Santen DK, Coutinho RA, van den Hoek A, van Brussel G, Buster M, Prins
Harm Reduct J. 2021 Jan; 18(1):2
- Micro-elimination of hepatitis C among people with HIV coinfection: declining incidence and prevalence accompanying a multi-center treatment scale-up trial.
Doyle JS, van Santen DK, Iser D, Sasadeusz J, O'Reilly M, Harney B, Traeger MW, Roney J, Cutts JC, Bowring AL, Winter R, Medland N, Fairley CK, Moore R, Tee B, Asselin J, El-Hayek C, Hoy JF, Matthews GV, Prins M, Stoové MA, Hellard ME
Clin Infect Dis. 2021 Jan; 73(7):e2164–e2172
2020 (5)
- The impact of markers of HIV infection on change in liver stiffness in people with HIV and hepatitis C virus co-infection after treatment and cure of hepatitis C.
van Santen DK, Agius PA, Sasadeusz J, Fairley KC, Sievert W, Gane E, Iser D, O'Reilly M, Medland NA, Moore R, Hellard ME, Hoy JF, Doyle JS
J Acquir Immune Defic Syndr. 2020 Aug; 85(5):e81-e89
- Hepatitis C elimination in people living with HIV - the importance of biomedical and behavioural interventions.
van Santen DK, Sacks-Davis R, Hellard M
J Int AIDS Soc. 2020 Jul; 23(7):e25589
- The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
Traeger MW, Pedrana AE, van Santen DK, Doyle JS, Howell J, Thompson AJ, El-Hayek C, Asselin J, Polkinghorne V, Membrey D, Bramwell F, Carter A, Guy R, Stoové MA, Hellard ME; EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS)
PLoS One. 2020 Jun; 15(6):e0235445
- Measuring hepatitis C virus elimination as a public health threat:beyond global targets.
van Santen DK, Sacks-Davis R, Doyle JS, Scott N, Prins M, Hellard M
J Viral Hepat. 2020 Mar; 27(8):770-773
- Commentary on Barre et al. (2019): Identifying remaining barriers to hepatitis C treatment in the DAA era.
Sacks-Davis R, van Santen DK, DoyleJS
Addiction. 2020 Jan; 115(3):583-584
2018 (2)
- High proportions of liver fibrosis and cirrhosis in an ageing population of people who use drugs in Amsterdam, The Netherlands.
Daniela K van Santen, Maarten F Schim van der Loeff, Judith Cartier van Dissel, Jonie P D Martens, Marc van der Valk, Maria Prins
Eur J Gastroenterol Hepatol. 2018 Oct; 30(10):1168-1176
- Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
Hannah Fraser, Natasha K Martin, Henrikki Brummer-Korvenkontio, Patrizia Carrieri, Olav Dalgard, John Dillon, David Goldberg, Sharon Hutchinson, Marie Jauffret-Roustide, Martin Kaberg, Amy A Matser, Mojca Maticic, Havard Midgard, Viktor Mravcik, Anne Ovrehus, Maria Prins, Jens Reimer, Geert Robaeys, Bernd Schulte, Daniela K van Santen, Ruth Zimmermann, Peter Vickerman, Matthew Hickman
J Hepatol. 2018 Mar; 68(3):402-411
2017 (3)
- HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985-2015.
Daniela K van Santen, Jannie J van der Helm, Karen Lindenburg, Maarten Schim van der Loeff, Maria Prins
Int J Drug Policy. 2017 Sep; 47:95-101
- Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990-2014.
Daniela Katinka van Santen, Jannie Johanna van der Helm, Julia Del Amo, Laurence Meyer, Antonella D'Arminio Monforte, Matt Price, Charles Antoine Beguelin, Robert Zangerle, Mette Sannes, Kholoud Porter, Ronald Bertus Geskus, Maria Prins
J Hepatol. 2017 Aug; 67(2):255-262
- Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators (including van Santen, D)
Lancet Gastroenterol Hepatol. 2017 May; 2(5):325-336
2016 (3)
- Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands.
Daniela K van Santen, Anneke S de Vos, Amy Matser, Sophie B Willemse, Karen Lindenburg, Mirjam E E Kretzschmar, Maria Prins, G Ardine de Wit
PLoS One. 2016 Oct; 11(10):e0163488
- Does provider-initiated HIV testing and counselling lead to higher HIV testing rate and HIV case finding in Rwandan clinics?
Felix R Kayigamba, Daniela Van Santen, Mirjam I Bakker, Judith Lammers, Veronicah Mugisha, Emmanuel Bagiruwigize, Ludwig De Naeyer, Anita Asiimwe, Maarten F Schim Van Der Loeff
BMC Infect Dis. 2016 Jan; 16:26
- The effect of HIV infection on anal and penile human papillomavirus incidence and clearance: a cohort study among MSM.
Sofie H Mooij, Daniela K van Santen, Ronald B Geskus, Marianne A B van der Sande, Roel A Coutinho, Ineke G Stolte, Peter J F Snijders, Chris J L M Meijer, Arjen G C L Speksnijder, Henry J C de Vries, Audrey J King, Arne van Eeden, Maarten F Schim van der Loeff
AIDS. 2016 Jan; 30(1):121-132
2015 (4)
- The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms.
S B Willemse, D Razavi-Shearer, F R Zuure, I K Veldhuijzen, E A Croes, A J van der Meer, D K van Santen, J M de Vree, R J de Knegt, H L Zaaijer, H W Reesink, M Prins, H Razavi
Neth J Med. 2015 Nov; 73(9):417-431
- Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.
V Saraswat, S Norris, R J de Knegt, J F Sanchez Avila, M Sonderup, E Zuckerman, P Arkkila, C Stedman, S Acharya, I Aho, A C Anand, M I Andersson, V Arendt, O Baatarkhuu, K Barclay, Z Ben-Ari, C Bergin, F Bessone, S Blach, N Blokhina, C R Brunton, G Choudhuri, V Chulanov, L Cisneros, E A Croes, Y A Dahgwahdorj, O Dalgard, J R Daruich, N R Dashdorj, D Davaadorj, M de Vree, C Estes, R Flisiak, A C Gadano, E Gane, W Halota, A Hatzakis, C Henderson, P Hoffmann, J Hornell, D Houlihan, S Hrusovsky, P Jarcuska, D Kershenobich, K Kostrzewska, P Kristian, M Leshno, Y Lurie, A Mahomed, N Mamonova, N Mendez-Sanchez, J Mossong, E Nurmukhametova, P Nymadawa, M Oltman, J Oyunbileg, Ts Oyunsuren, G Papatheodoridis, N Pimenov, N Prabdial-Sing, M Prins, P Puri, S Radke, A Rakhmanova, H Razavi, K Razavi-Shearer, H W Reesink, E Ridruejo, R Safadi, O Sagalova, R Sanduijav, I Schreter, C Seguin-Devaux, S R Shah, I Shestakova, A Shevaldin, O Shibolet, S Sokolov, K Souliotis, C W Spearman, T Staub, E A Strebkova, D Struck, K Tomasiewicz, L Undram, A J van der Meer, D van Santen, I Veldhuijzen, F G Villamil, S Willemse, F R Zuure, M O Silva, V Sypsa, E Gower
J Viral Hepat. 2015 Jan; 22 Suppl 1:6-25
- Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.
E Gane, D Kershenobich, C Seguin-Devaux, P Kristian, I Aho, O Dalgard, I Shestakova, P Nymadawa, S Blach, S Acharya, A C Anand, M I Andersson, V Arendt, P Arkkila, O Baatarkhuu, K Barclay, Z Ben-Ari, C Bergin, F Bessone, N Blokhina, C R Brunton, G Choudhuri, V Chulanov, L Cisneros, E A Croes, Y A Dahgwahdorj, J R Daruich, N R Dashdorj, D Davaadorj, R J de Knegt, M de Vree, A C Gadano, E Gower, W Halota, A Hatzakis, C Henderson, P Hoffmann, J Hornell, D Houlihan, S Hrusovsky, P Jarcuska, K Kostrzewska, M Leshno, Y Lurie, A Mahomed, N Mamonova, N Mendez-Sanchez, J Mossong, S Norris, E Nurmukhametova, M Oltman, J Oyunbileg, Ts Oyunsuren, G Papatheodoridis, N Pimenov, M Prins, P Puri, S Radke, A Rakhmanova, H Razavi, K Razavi-Shearer, H W Reesink, E Ridruejo, R Safadi, O Sagalova, J F Sanchez Avila, R Sanduijav, V Saraswat, I Schreter, S R Shah, A Shevaldin, O Shibolet, M O Silva, S Sokolov, M Sonderup, K Souliotis, C W Spearman, T Staub, C Stedman, E A Strebkova, D Struck, V Sypsa, K Tomasiewicz, L Undram, A J van der Meer, D van Santen, I Veldhuijzen, F G Villamil, S Willemse, E Zuckerman, F R Zuure, N Prabdial-Sing, R Flisiak, C Estes
J Viral Hepat. 2015 Jan; 22 Suppl 1:46-73
- The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.
A Hatzakis, V Chulanov, A C Gadano, C Bergin, Z Ben-Ari, J Mossong, I Schreter, O Baatarkhuu, S Acharya, I Aho, A C Anand, M I Andersson, V Arendt, P Arkkila, K Barclay, F Bessone, S Blach, N Blokhina, C R Brunton, G Choudhuri, L Cisneros, E A Croes, Y A Dahgwahdorj, O Dalgard, J R Daruich, N R Dashdorj, D Davaadorj, R J de Knegt, M de Vree, C Estes, R Flisiak, E Gane, E Gower, W Halota, C Henderson, P Hoffmann, J Hornell, D Houlihan, S Hrusovsky, P Jarcuska, D Kershenobich, K Kostrzewska, P Kristian, M Leshno, Y Lurie, A Mahomed, N Mamonova, N Mendez-Sanchez, S Norris, E Nurmukhametova, P Nymadawa, M Oltman, J Oyunbileg, Ts Oyunsuren, G Papatheodoridis, N Pimenov, N Prabdial-Sing, M Prins, S Radke, A Rakhmanova, K Razavi-Shearer, H W Reesink, E Ridruejo, R Safadi, O Sagalova, J F Sanchez Avila, R Sanduijav, V Saraswat, C Seguin-Devaux, S R Shah, I Shestakova, A Shevaldin, O Shibolet, M O Silva, S Sokolov, M Sonderup, K Souliotis, C W Spearman, T Staub, C Stedman, E A Strebkova, D Struck, V Sypsa, K Tomasiewicz, L Undram, A J van der Meer, D van Santen, I Veldhuijzen, F G Villamil, S Willemse, E Zuckerman, F R Zuure, P Puri, H Razavi
J Viral Hepat. 2015 Jan; 22 Suppl 1:26-45
2014 (1)
News Articles (1)
2023 (1)
